PE20181515A1 - BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS - Google Patents

BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS

Info

Publication number
PE20181515A1
PE20181515A1 PE2018001063A PE2018001063A PE20181515A1 PE 20181515 A1 PE20181515 A1 PE 20181515A1 PE 2018001063 A PE2018001063 A PE 2018001063A PE 2018001063 A PE2018001063 A PE 2018001063A PE 20181515 A1 PE20181515 A1 PE 20181515A1
Authority
PE
Peru
Prior art keywords
wnt signaling
tumor cells
polypeptides
methods
biparatopic polypeptides
Prior art date
Application number
PE2018001063A
Other languages
Spanish (es)
Inventor
Vittoria Zinzalla
Klaus-Peter Kuenkele
Marie-Ange Buyse
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20181515A1 publication Critical patent/PE20181515A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion proporciona polipeptidos de fijacion de reaccion cruzada con LRP5/LRP6 biparatopicos novedosos y, mas especificamente, constructos de dominio variable unico de inmunoglobulina de reaccion cruzada con LRP5/LRP6 biparatopicos novedosos que pueden inhibir las vias de senalizacion Wnt. La invencion tambien se refiere a secuencias especificas de estos polipeptidos, metodos para su fabricacion y metodos para usarlos, que incluyen metodos para el tratamiento de enfermedades, tales como cancer.The invention provides novel biparatopic LRP5 / LRP6 cross-reactive polypeptides and, more specifically, novel biparatopic LRP5 / LRP6 cross-reactive immunoglobulin single variable domain constructs that can inhibit Wnt signaling pathways. The invention also relates to specific sequences of these polypeptides, methods for their manufacture and methods for using them, including methods for the treatment of diseases, such as cancer.

PE2018001063A 2015-12-04 2016-12-02 BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS PE20181515A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15197999 2015-12-04

Publications (1)

Publication Number Publication Date
PE20181515A1 true PE20181515A1 (en) 2018-09-21

Family

ID=54782606

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001063A PE20181515A1 (en) 2015-12-04 2016-12-02 BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS

Country Status (34)

Country Link
US (2) US10597449B2 (en)
EP (2) EP3797790A1 (en)
JP (2) JP6728355B2 (en)
KR (1) KR20180081825A (en)
CN (1) CN108289943B (en)
AR (1) AR106949A1 (en)
AU (1) AU2016363787B2 (en)
BR (1) BR112018010537A2 (en)
CA (1) CA3006235A1 (en)
CL (1) CL2018001384A1 (en)
CO (1) CO2018005680A2 (en)
CY (1) CY1123454T1 (en)
DK (1) DK3383425T3 (en)
EA (1) EA201891331A1 (en)
ES (1) ES2821099T3 (en)
HK (1) HK1255725A1 (en)
HR (1) HRP20201528T1 (en)
HU (1) HUE051777T2 (en)
IL (1) IL259119B (en)
LT (1) LT3383425T (en)
MA (2) MA43368B1 (en)
MX (1) MX2018006760A (en)
MY (1) MY200933A (en)
PE (1) PE20181515A1 (en)
PH (1) PH12018501155A1 (en)
PL (1) PL3383425T3 (en)
PT (1) PT3383425T (en)
RS (1) RS60823B1 (en)
SA (1) SA518391728B1 (en)
SG (1) SG11201804510PA (en)
SI (1) SI3383425T1 (en)
TW (1) TWI734719B (en)
UA (1) UA122079C2 (en)
WO (1) WO2017093478A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968742T3 (en) 2012-02-28 2024-05-13 Novartis Ag Selection of cancer patients for administration of Wnt signaling inhibitors using Rnf43 mutational status
EA201891165A1 (en) 2015-11-18 2018-11-30 Мерк Шарп И Доум Корп. MOLECULES BINDING PD1 AND / OR LAG3
CA3006235A1 (en) 2015-12-04 2017-06-08 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing wnt signaling in tumor cells
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
AU2018276409A1 (en) * 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
JP2020530454A (en) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Platform for producing safe cell therapies
US11365250B2 (en) * 2017-11-29 2022-06-21 The Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP3947455A1 (en) 2019-03-29 2022-02-09 Boehringer Ingelheim International GmbH Anticancer combination therapy
US11578129B2 (en) 2019-03-29 2023-02-14 Boehringer Ingelheim International Gmbh LRP5 and PD-1 antagonist anticancer combination therapy
CN114040926A (en) 2019-05-04 2022-02-11 印希比股份有限公司 Polypeptide binding to CD123 and uses thereof
WO2020227481A1 (en) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cd123 targeted immunotherapies
MX2022001947A (en) * 2019-08-14 2022-06-14 Modmab Therapeutics Inc Antibodies that bind to lrp5 proteins and methods of use.
WO2021026666A1 (en) * 2019-08-14 2021-02-18 Modmab Therapeutics Inc. Antibodies that bind to lrp6 proteins and methods of use
CN112794914B (en) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 ALK nano antibody developed based on phage display technology and application thereof
WO2021163490A1 (en) * 2020-02-14 2021-08-19 University Of Washington Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion
US20220348659A1 (en) * 2021-03-24 2022-11-03 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
JPWO2023286854A1 (en) * 2021-07-16 2023-01-19
CN116375851B (en) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 Nanometer antibody of anti-avian influenza virus NP protein, preparation method and application thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427968T1 (en) 1992-08-21 2009-04-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAIN
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
JP4303105B2 (en) 2001-06-28 2009-07-29 ドマンティス リミテッド Dual specific ligands and their use
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP5113523B2 (en) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ Polypeptides comprising nanoantibodies against amyloid-β and nanoantibodies TM for the treatment of neurodegenerative diseases such as Alzheimer's disease
DK2949668T3 (en) 2005-05-18 2019-11-11 Ablynx Nv IMPROVED NANOBODIES TM AGAINST TUMOR CANCER FACTOR-ALFA
US7622267B2 (en) * 2006-05-30 2009-11-24 Van Andel Research Institute Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods
WO2007142298A1 (en) 2006-06-08 2007-12-13 Nsk Ltd. Shell needle bearing with seal ring and its manufacturing method
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN100428934C (en) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 Application of cumarin kind compound in preparation of medicine for inducing nerve stem cell orienting differentiation
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
JP2010511397A (en) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． Peptides that can bind to serum proteins
BRPI0820327A2 (en) 2007-11-02 2020-10-06 Novartis Ag molecules and methods for protein modulation related to low density 6 lipoprotein receptor (lrp6)
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
JP2011516603A (en) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． Peptides capable of binding to serum proteins and compounds, constructs and polypeptides containing them
US8661423B2 (en) 2009-05-01 2014-02-25 Telcordia Technologies, Inc. Automated determination of quasi-identifiers using program analysis
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
BR112012017051A2 (en) 2009-12-23 2017-12-05 Esbatech Alcon Biomed Res Unit method to decrease immunogenicity
JP2013518853A (en) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． Peptides capable of binding to serum albumin and compounds, constructs and polypeptides containing the same
MA34025B1 (en) 2010-03-03 2013-02-01 Boehringer Ingelheim Int POLYPEPTIDES BINDING TO BETA-A
BR112012022044A2 (en) * 2010-03-24 2020-08-25 Genentech Inc ''antibody, immunoconjugate, pharmaceutical formulation, antibody use, treatment method, isolated bispecific antibody and host cell''.
BR112012028326A2 (en) * 2010-05-06 2017-03-21 Novartis Ag isolated multivalent antibody, isolated biparatopic antibodies, nucleic acid, vector, pharmaceutical composition, method of obtaining said antibodies and use thereof
ES2949159T3 (en) 2010-05-06 2023-09-26 Novartis Ag Compositions and methods of use for low-density lipoprotein-related protein 6 (LRP6) therapeutic antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
KR102240318B1 (en) 2011-06-23 2021-04-15 아블린쓰 엔.브이. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2813432T3 (en) 2011-08-17 2021-03-23 Glaxo Group Ltd Modified proteins and peptides
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
JP5949270B2 (en) 2012-07-24 2016-07-06 富士通株式会社 Audio decoding apparatus, audio decoding method, and audio decoding computer program
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
CA3006235A1 (en) * 2015-12-04 2017-06-08 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing wnt signaling in tumor cells

Also Published As

Publication number Publication date
WO2017093478A1 (en) 2017-06-08
US20200199222A1 (en) 2020-06-25
TW201731868A (en) 2017-09-16
US11952418B2 (en) 2024-04-09
PH12018501155A1 (en) 2019-01-28
RS60823B1 (en) 2020-10-30
JP2020178701A (en) 2020-11-05
UA122079C2 (en) 2020-09-10
ES2821099T3 (en) 2021-04-23
SA518391728B1 (en) 2022-03-28
HK1255725A1 (en) 2019-08-23
HRP20201528T1 (en) 2020-12-11
DK3383425T3 (en) 2020-09-28
CO2018005680A2 (en) 2018-06-12
EA201891331A1 (en) 2018-12-28
BR112018010537A2 (en) 2018-11-13
CA3006235A1 (en) 2017-06-08
AU2016363787B2 (en) 2023-02-02
US10597449B2 (en) 2020-03-24
HUE051777T2 (en) 2021-03-29
MA43368B1 (en) 2020-09-30
EP3383425A1 (en) 2018-10-10
LT3383425T (en) 2020-10-12
SI3383425T1 (en) 2020-11-30
PL3383425T3 (en) 2021-01-11
MA54648A (en) 2021-11-10
CN108289943A (en) 2018-07-17
MY200933A (en) 2024-01-24
PT3383425T (en) 2020-10-07
US20170174762A1 (en) 2017-06-22
CL2018001384A1 (en) 2018-09-14
IL259119A (en) 2018-06-28
JP6728355B2 (en) 2020-07-22
EP3383425B1 (en) 2020-07-15
JP2019506841A (en) 2019-03-14
CN108289943B (en) 2023-06-20
KR20180081825A (en) 2018-07-17
CY1123454T1 (en) 2022-03-24
AR106949A1 (en) 2018-03-07
MA43368A (en) 2018-10-10
IL259119B (en) 2022-04-01
MX2018006760A (en) 2018-08-01
AU2016363787A1 (en) 2018-05-17
TWI734719B (en) 2021-08-01
SG11201804510PA (en) 2018-06-28
EP3797790A1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
PE20181515A1 (en) BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS
CO2019012329A2 (en) Polypeptides that antagonize wnt signaling in tumor cells
CY1122314T1 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS
CY1122415T1 (en) CYCLOPYLAMINES AS LSD1 INHIBITORS
ECSP17062716A (en) BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
CL2017001459A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
ECSP17083788A (en) ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGIC MALIGNANT DISEASES
CR20150255A (en) THYMPHENE FUSIONATED TRICICLIC DERIVATIVES AS JAK INHIBITORS
ECSP15043772A (en) TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
CR20160542A (en) 1 H-PIRROLO [2,3-c] PIRIDIN-7 (6H) -ONAS YPIRAZOLO [3,4-c] PlRIDIN-7 (6H) -ONAS AS BET PROTEIN INHIBITORS
PE20170441A1 (en) ANTIBODIES AGAINST THE GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND ITS USES
DK3286206T3 (en) UNKNOWN HYBRID ACTRIIB-LIGAND-TRAP PROTEINS FOR THE TREATMENT OF MUSCLE WIND DISEASES
UY37018A (en) PAD4 BICYCLIC INHIBITORS
EA201890185A1 (en) METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID
EA201891376A1 (en) BENZOTIOPHENE SELECTIVE BLOCKS OF ESTROGEN RECEPTORS
EA201692269A1 (en) NEW COMPOSITIONS, THEIR USE AND METHODS OF OBTAINING
CL2018002810A1 (en) Anti-complement factor bb antibodies and uses of these cross-reference.
UY33956A (en) ANTIBODY OF THE HUMAN ANTITISULAR FACTOR AND ITS USES TO TREAT CANCER
CL2017001135A1 (en) Enhanced antibodies against il-6
CL2018001652A1 (en) Compositions and methods to reduce tau expression
MX2015011518A (en) Met-binding agents and uses thereof.
UY37980A (en) NOVELTY COMPOUNDS TO TREAT PARASITIC DISEASES
CO2019012475A2 (en) Novel fragrance compositions and products with mood-enhancing effects
EA201791814A1 (en) IMIDAZOLYL TRYCYCLIC ENONS AS ANTIOXIDANT INFLAMMATION MODULATORS
BR112018068798A2 (en) compositions and methods for treating parasitic diseases